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ORIGINAL INVESTIGATION
The soluble guanylate cyclase activator 
cinaciguat prevents cardiac dysfunction in a rat 
model of type-1 diabetes mellitus
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Abstract 
Background: Diabetes mellitus (DM) leads to the development of diabetic cardiomyopathy, which is associated with 
altered nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine monophosphate (cGMP) signalling. 
Cardioprotective effects of elevated intracellular cGMP‑levels have been described in different heart diseases. In the 
current study we aimed at investigating the effects of pharmacological activation of sGC in diabetic cardiomyopathy.
Methods: Type‑1 DM was induced in rats by streptozotocin. Animals were treated either with the sGC activator 
cinaciguat (10 mg/kg/day) or with placebo orally for 8 weeks. Left ventricular (LV) pressure–volume (P–V) analysis was 
used to assess cardiac performance. Additionally, gene expression (qRT‑PCR) and protein expression analysis (western 
blot) were performed. Cardiac structure, markers of fibrotic remodelling and DNA damage were examined by histol‑
ogy, immunohistochemistry and TUNEL assay, respectively.
Results: DM was associated with deteriorated cGMP signalling in the myocardium (elevated phosphodiesterase‑5 
expression, lower cGMP‑level and impaired PKG activity). Cardiomyocyte hypertrophy, fibrotic remodelling and DNA 
fragmentation were present in DM that was associated with impaired LV contractility (preload recruitable stroke work 
(PRSW): 49.5 ± 3.3 vs. 83.0 ± 5.5 mmHg, P < 0.05) and diastolic function (time constant of LV pressure decay (Tau): 
17.3 ± 0.8 vs. 10.3 ± 0.3 ms, P < 0.05). Cinaciguat treatment effectively prevented DM related molecular, histological 
alterations and significantly improved systolic (PRSW: 66.8 ± 3.6 mmHg) and diastolic (Tau: 14.9 ± 0.6 ms) function.
Conclusions: Cinaciguat prevented structural, molecular alterations and improved cardiac performance of the dia‑
betic heart. Pharmacological activation of sGC might represent a new therapy approach for diabetic cardiomyopathy.
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Background
Diabetes mellitus (DM) is associated with cardiovascu-
lar complications, such as myocardial infarction, chronic 
heart failure or vascular diseases. It acts as an independ-
ent risk factor for coronary atherosclerosis and ischemic 
heart disease, however, the altered metabolic state—due 
to elevated glucose levels—has a direct impact on cardiac 
structure and function independently of coronary artery 
disease. Thus DM leads to the development of a spe-
cial disease entity, termed diabetic cardiomyopathy [1]. 
Although, both systolic and diastolic dysfunction [2–5] 
as well as several key morphological and cellular/sub-
cellular features (including myocardial fibrotic remodel-
ling, cardiomyocyte hypertrophy, nitro-oxidative stress, 
inflammation and apoptosis) have been described in 
diabetic cardiomyopathy, the exact mechanisms in the 
pathophysiology are still unknown [1, 6–9].
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In the cardiovascular system, under physiological con-
ditions, nitric oxide (NO) is produced by the endothelial 
nitric oxide synthase (eNOS) in endothelial cells and dif-
fuses into target cells, such as vascular smooth muscle 
cells or cardiomyocytes. It activates its intracellular recep-
tor, the soluble guanylate cyclase enzyme (sGC) which 
results in the rapid formation of the second messenger 
cyclic guanosine monophosphate (cGMP). cGMP acti-
vates the cGMP-dependent protein kinase (PKG), which 
mediates most of its physiological effects, such as vasodil-
atation or inhibition of platelet aggregation [10]. The NO–
sGC–cGMP–PKG signalling pathway has been described 
to get disturbed in DM through several mechanisms, 
such as increased formation of reactive nitrogen (RNS) 
and oxygen species (ROS) (nitro-oxidative stress), eNOS 
uncoupling and decreased NO bioavailability, increased 
expression of the cGMP-degrading enzyme phosphodies-
terase (PDE)-5 [1]. Our research group and others dem-
onstrated protective effects of enhanced cGMP-signalling 
via pharmacological inhibition of PDE-5 in several cardio-
vascular diseases [11–15] and in DM in particular [3, 16].
Nitro-oxidative stress directly deteriorates the struc-
ture of sGC resulting in a heme-deficient, NO-insensitive 
and inactive form of the enzyme [17]. Therefore, drugs 
that are able to activate the NO-insensitive form of sGC 
thus reactivating it might have cardioprotective effects 
in various pathological conditions through the enhance-
ment of the impaired cGMP-signalling. The sGC activa-
tor cinaciguat (BAY 58-2667) has been reported to bind 
to the heme pocket of NO-insensitive sGC [17] thus 
increasing its cGMP-producing activity and augment-
ing cGMP-PKG signalling. Recent studies described its 
beneficial effects in experimental myocardial infarction 
[18], myocardial ischemia/reperfusion injury [19, 20], 
endothelial dysfunction induced by nitro-oxidative stress 
[21], vascular neointima formation [22] or in prevention 
of cardiomyocyte hypertrophy [23].
The safety and tolerability of cinaciguat have been 
assessed by phase-I human clinical trials [24]. Although 
cinaciguat has demonstrated efficacy in a proof-of-con-
cept study in patients with acute decompensated heart 
failure [25], the phase-IIb clinical studies for the same 
indication has been terminated prematurely due to the 
high number of adverse events (mainly a significant drop 
of blood pressure) during acute intravenous applica-
tion [26, 27]. The investigators concluded that rather a 
chronic, long term oral administration of the compound 
could improve endothelial and preserve myocardial func-
tion in heart failure patients [28].
Based upon the concept of cardioprotection by 
enhanced cGMP-signalling via chronic pharmacologi-
cal activation of the sGC enzyme, we investigated in the 
present study whether long-term administration of the 
sGC-activator cinaciguat can preserve left ventricular 
(LV) systolic and diastolic function and prevent DM-
associated myocardial alterations in the rat model of 
streptozotocin (STZ)-induced experimental type-1 DM.
Methods
Animals
The investigation conformed to the EU Directive 
2010/63/EU guidelines and the Guide for the Care and 
Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85–23, revised 
1996) and was reviewed and approved by the appropri-
ate institutional and national ethical committees (permis-
sion number: 22.1/1162/3/2010). All animals received 
humane care.
8-week-old male Sprague–Dawley rats (n  =  46; body 
weight (BW): 225–250  g) (Charles River, Sulzfeld, Ger-
many) were housed individually in a room (constant tem-
perature, 12/12 h light/dark cycles) and received standard 
laboratory rat diet and water ad libitum.
Induction of DM
Type-1 DM was induced with a single i.p. injection of 
STZ (60  mg/kg) in our rats as described previously [3]. 
STZ was freshly dissolved in citrate buffer (0.1 M). Con-
trol animals received only the buffer. 72 h after the injec-
tion a drop of blood was collected from the tail vein and 
blood glucose concentration was determined by using a 
digital blood glucose meter (Accu-Chek® Sensor, Roche, 
Mannheim, Germany). Animals with a random blood 
glucose level >15 mmol/l were considered to be diabetic 
and were included into the study.
Experimental groups, chronic treatment protocol
After confirmation of DM, rats were randomised into 
four groups: vehicle-treated control (Co; n  =  12), 
cinaciguat-treated control (CoCin; n  =  12), vehicle-
treated diabetic (DiabCo; n = 12) and cinaciguat-treated 
diabetic (DiabCin; n = 10) groups. Animals were treated 
for 8 weeks with 0.5 % methylcellulose (Co, DiabCo) vehi-
cle or with the sGC activator cinaciguat in suspension 
p.o. (CoCin, DiabCin; 10 mg/kg/day), starting immeadi-
ately after DM confirmation. Water bottles were filled 
every morning with the same amount of fresh tap water 
and daily water intake was measured. Animal cages were 
handled with care and were not moved after water bottle 
replacement to prevent spilling of water from the bottles. 
Body weight of the animals were recorded every 2  days 
and the dose of cinaciguat was adjusted accordingly.
Hemodynamic measurements
24–28 h after the last administration of cinaciguat/vehi-
cle, LV pressure–volume (P–V) analyses were carried 
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out using a pressure-conductance microcatheter system 
(MPVS-Ultra, Millar Instruments, Houston, TX, USA) 
to evaluate LV performance. Animals were anesthe-
tised with a mixture of xylazine (3  mg/kg) and ketamin 
(100  mg/kg) i.p. [3, 29]. Mean arterial blood pressure 
(MAP), heart rate (HR), maximal LV systolic pressure 
(LVSP), LV end-diastolic pressure (LVEDP), maximal 
slope of systolic pressure increment (dP/dtmax) and dias-
tolic pressure decrement (dP/dtmin), time constant of LV 
pressure decay (Tau), ejection fraction (EF), stroke work 
(SW) and cardiac output (CO) were calculated. The slope 
(Ees) of the LV end-systolic P–V relationships (ESPVR; 
according to the parabolic curvilinear model) and preload 
recruitable stroke work (PRSW) were calculated as load-
independent indexes of LV contractility while the slope 
of the LV end-diastolic P–V relationship (EDPVR) was 
calculated as reliable index of LV diastolic stiffness. For 
detailed hemodynamic description see Additional file 1.
Biochemical measurements
A drop of blood was collected from the tail vein and 
blood glucose concentration was determined using a dig-
ital blood glucose meter (Accu-Chek® Sensor, Roche). At 
the end of the hemodynamic measurements blood was 
collected from the inferior caval vein, plasma samples 
were prepared and stored at −80 °C.
Plasma cGMP levels were determined by enzyme 
immunoassay (EIA) using a commercial kit (Amersham 
cGMP EIA Biotrak System, GE Healthcare, Buckingham-
shire, UK).
Myocardial mRNA analysis
We performed quantitative real-time polymerase chain 
reaction (qRT-PCR) experiments as described previ-
ously [30]. Frozen LV samples were homogenised, total 
RNA was isolated. Reverse transcription was performed 
and cDNA samples were amplified on the StepOnePlus™ 
Real-Time PCR System (Applied Biosystems, Foster 
City, CA, USA) using TaqMan® Universal PCR Mas-
terMix and TaqMan® Gene Expression Assays (Applied 
Biosystems) for the following targets: atrial natriuretic 
factor (ANF), α myosin heavy chain (MHC) and β-MHC 
(ratio of β/α-MHC expression was assessed as patholog-
ical cardiomyocyte hypertrophy marker), antiapoptotic 
mediator B cell CLL/lymphoma-2 (Bcl-2), proaptotic 
mediator Bcl2-associated X protein (BAX), eNOS, 
mediators of cardiac remodelling such as collagen 1a1 
(Col1), 3a1 (Col3) and fibronectin, matrix metallopepti-
dase (MMP)-2 and MMP-9 and their endogenous inhib-
itors tissue inhibitor of MMP (TIMP)-1 and TIMP-2, 
members of different antioxidant systems like cata-
lase, thioredoxin-1, gluthatione-reductase, superoxide 
dismutase (SOD)-2 and heat shock 70 kD protein 1A 
(HSP70a1). Gene expression data were normalised to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
The mRNA expression levels were calculated using the 
CT comparative method (2−ΔCT) and adjusted to a posi-
tive calibrator. For detailed description see Additional 
file 1.
Immunoblot analysis
LV tissue samples were homogenised, protein concen-
tration was determined and equal amounts of protein 
were separated via gel-electrophoresis. Proteins were 
transferred to nitrocellulose membranes. After block-
ing, membranes were incubated with primary antibodies 
against various targets: eNOS (1:1000, SC-654, San-
taCruz Biotechnology, Santa Cruz, CA, USA), sGC β1 
(1:1000, NB100-91798, Novus Biologicals, Cambridge, 
UK), PDE-5 (1:2000, ALX-210-099, Enzo Life Sciences, 
Farmingdale, NY, USA), PKG (1:2000, ADI-KAP-PK005-
F, Enzo Life Sciences), vasodilator-stimulated phos-
phoprotein (VASP) and phospho-VASP (1:1000, 3112 
and 1:2000, 3114, Cell Signaling, Danvers, MA, USA) as 
marker of PKG activity, profibrotic mediator transform-
ing growth factor (TGF)-β1 (1:250, SC-146, SantaCruz 
Biotechnology), MMP-2 (1:5000, NB200-193, Novus Bio-
logicals) and MMP-9 (1:1000, SC-6840, SantaCruz Bio-
technology). After washing, membranes were incubated 
in horseradish peroxidase-conjugated secondary anti-
body. Immunoblots were developed by enhanced chemi-
luminescence detection. Protein band densities were 
quantified using GeneTools software (Syngene, Freder-
ick, MD, USA). After adjusting protein band densities 
to GAPDH (1:10000, MAB374, Millipore, Billerica, MA, 
USA), band density values were normalised to the aver-
age value of the Co group for statistical analysis. Detailed 
description of immunoblot analysis is available as Addi-
tional file 1.
Histology, immunohistochemistry
LV sections were stained with hematoxylin-eosin (H&E) 
and Masson’s trichrome (MT) to examine histopatho-
logical characteristics and interstitial myocardial fibrotic 
remodelling, respectively. To evaluate cardiomyocyte 
hypertrophy, transverse transnuclear widths (cardiomyo-
cyte diameter) were measured of 100 longitudinally ori-
ented, mono-nucleated cardiomyocytes on H&E stained 
LV sections cut on the same plane. Immunohistochem-
istry for the fibrosis marker fibronectin (Sigma-Aldrich, 
Budapest, Hungary), for the profibrotic mediator TGF-β1 
(Santa Cruz Biotechnology), for the sGC derived second 
messenger cGMP (AbD Serotec, Düsseldorf, Germany) 
and for the nitro-oxidative stress marker nitrotyrosine 
(NT) (Millipore) were performed and analysed. Histolog-
ical and immunohistochemical analyses were performed 
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by two blinded observers. For detailed description see 
Additional file 1.
Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay
TUNEL assay was performed to detect DNA strand 
breaks using a commercial kit (DeadEnd™ Colorimet-
ric TUNEL System, Promega, Mannheim, Germany). 
TUNEL positive cell nuclei were counted in 20 randomly 
selected fields of each section by two blinded observers. 
Data were normalised to the mean value of the Co group 
for statistical analysis.
Drugs
The sGC activator cinaciguat (BAY 58-2667; 4-({(4-car-
boxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phe-
nyl)ethyl]amino}methyl)benzoic acid) was provided by 
Bayer HealthCare (Wuppertal, Germany) for oral appli-
cation. Cinaciguat was suspended in 0.5  % methylcellu-
lose solution. STZ was purchased from Sigma-Aldrich 
(Taufkirchen, Germany).
Statistics
Data are presented as means and standard errors of the 
mean (SEM). After testing normal distribution of the 
data, two-factorial analysis of variance (ANOVA) (with 
diabetes and drug treatment as factors) was carried out. 
A P value of <0.05 was used as a criterion of signifi-
cance. Where F value of diabetes  ×  treatment interac-
tion reached the level of significance Tukey HSD post hoc 
testing was performed to evaluate differences between 
the groups. Data that did not show normal distribution 
were transformed logarithmically before performing 
two-factorial ANOVA.
Results
Body weight, heart weight (HW) and glucose levels
All animals survived the study period and reached the 
end-point of the investigation. HW and BW significantly 
decreased in both diabetic groups while HW to BW ratio 
increased in the diabetic groups (Table 1). When compared 
with controls, DM led to significantly increased blood glu-
cose levels and daily water intake. Cinaciguat treatment in 
diabetic rats did not influence blood glucose levels, but led 
to attenuated water intake (Table 1). Time-course of body 
weight changes is available as Additional file 2: Figure S1.
Effects of cinaciguat on plasma and myocardial cGMP 
levels in DM
Cinaciguat treatment had no effect on plasma cGMP levels 
in control animals (Fig.  1a), however it resulted in a pro-
nounced increase of plasma cGMP in DM (Fig. 1a). Accord-
ing to cGMP immunohistochemistry, the cGMP content of 
LV myocardium was significantly lower in DM than in con-
trols (Fig. 1b, c). However, chronic treatment with cinaciguat 
restored cGMP to the control level (Fig. 1b, c).
Effects of diabetes mellitus and cinaciguat treatment 
on myocardial nitro‑oxidative stress
DM was associated with increased NT immunoreactiv-
ity in LV myocardium referring to pronounced nitro-
oxidative stress which was significantly alleviated by 
cinaciguat treatment (Fig.  2a, b). Increased expression 
of HSP70a1, catalase, gluthatione-reductase and thiore-
doxin-1 was found in DM (Fig. 2c). HSP70a1 and glutha-
tione-reductase mRNA expression in the DiabCin group 
remained on the level of healthy controls (Fig. 2c). SOD-2 
expression did not show any difference among the groups 
(Fig. 2c).
Table 1 Basic characteristics of study groups
The values of blood glucose, daily water intake, heart weight, body weight (BW) and heart weight to body weight ratio are shown of the study groups—vehicle-
treated controls (Co), cinaciguat-treated controls (CoCin), vehicle-treated diabetic (DiabCo) and cinaciguat-treated diabetic (DiabCin) groups. Values are mean ± SEM 
of 10–12 experiments per group
* P < 0.05 vs. Co
† P < 0.05 vs. DiabCo (Tukey HSD test)
Characteristic Co CoCin DiabCo DiabCin Pdiabetes Ptreatment Pinteraction
Blood glucose (mmol/l) 5.8 ± 0.1 6.2 ± 0.1 30.8 ± 0.5* 29.3 ± 1.4* <0.001 0.460 0.209
Water intake (ml/gBW/day) 0.078 ± 0.002 0.090 ± 0.002 0.787 ± 0.006* 0.597 ± 0.013*† <0.001 <0.001 <0.001
Heart weight (g) 1.20 ± 0.06 1.24 ± 0.07 0.91 ± 0.04* 0.84 ± 0.03* <0.001 0.805 0.278
Body weight (g) 480.7 ± 17.6 477.8 ± 20.9 293.5 ± 11.1* 247.6 ± 14.8* <0.001 0.150 0.202
Heart weight/body weight 0.249 ± 0.008 0.259 ± 0.008 0.311 ± 0.009* 0.348 ± 0.015* <0.001 0.026 0.196
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Cinaciguat protects against DM related alteration of the 
NO‑sGC‑cGMP‑PKG signalling
Protein expression of eNOS and sGC β1 did not differ 
between healthy and diabetic rats (Fig.  3a) while eNOS 
gene expression was significantly lower in both diabetic 
groups (Fig.  3b). We detected elevated PDE-5 and PKG 
protein expression in the DiabCo group (Fig. 3a) whereas 
the p-VASP/VASP ratio (marker of PKG activity) was sig-
nificantly reduced, showing severe deterioration of PKG 
signalling in DM (Fig.  3a). Application of cinaciguat in 
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Fig. 1 Effect of diabetes mellitus (DM) and cinaciguat treatment on plasma and myocardial cyclic guanosine monophosphate (cGMP) content. a 
Result of plasma cGMP enzyme immunoassay. b Quantification of cGMP (P value of diabetes × treatment interaction in the two‑factorial ANOVA, 
Pinteraction = 0.025) immunohistochemistry. c Representative images of cGMP immunohistochemistry. Magnification: ×400, Scale bar 40 µm. Groups: 
vehicle‑treated control (Co), cinaciguat‑treated control (CoCin), vehicle‑treated diabetic (DiabCo) and cinaciguat‑treated diabetic (DiabCin). Bar 
graphs represent mean ± SEM of 9–11 experiments per group. *P < 0.05 vs. Co, †P < 0.05 vs. DiabCo (Tukey HSD test)
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Fig. 2 Cinaciguat treatment alleviates diabetes mellitus related oxidative stress. a Representative images of nitrotyrosine (NT) immunohistochem‑
istry. Magnification: ×200, Scale bar 40 µm. b Quantification of NT immunohistochemistry (P value of diabetes × treatment interaction in the 
two‑factorial ANOVA, Pinteraction <0.001) (n = 9–11/group). (c) Relative mRNA expression of catalase, gluthatione‑reductase (Pinteraction = 0.046), heat 
shock 70 kD protein 1A (HSP70a1) (Pinteraction = 0.021), superoxide dismutase (SOD)‑2 and thioredoxin‑1 (n = 5–6/group). Groups: vehicle‑treated 
control (Co), cinaciguat‑treated control (CoCin), vehicle‑treated diabetic (DiabCo) and cinaciguat‑treated diabetic (DiabCin). Bar graphs represent 
mean ± SEM. *P < 0.05 vs. Co, †P < 0.05 vs. DiabCo (Tukey HSD test)
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diabetic animals significantly reduced the expression of 
PDE-5, markedly increased PKG activity (as indicated by 
elevated p-VASP/VASP ratio) (Fig. 3a), while the expres-
sion of PKG did not differ between the two diabetic 
groups (Fig. 3a).
Cinaciguat treatment protects against DM related fibrotic 
remodelling of the myocardium
DM was associated with dysregulation of the MMP sys-
tem indicated by markedly increased MMP-9/TIMP-1 
and reduced MMP-2/TIMP-2 gene expression ratios 
(Fig.  4a). These alterations were attenuated in the 
DiabCin group (Fig. 4a). Although fibronectin expression 
remained unchanged, Col1 and Col3 expression levels 
were significantly lower in both diabetic groups (Fig. 4a). 
The profibrotic TGF-β1 showed increased expression in 
the diabetic animals, which was significantly ameliorated 
by cinaciguat (Fig.  4c). Expression of MMP-9 showed 
a twofold increase in DM, while MMP-2 remained 
unchanged (Fig. 4c). Cinaciguat did not significantly alter 
these parameters (Fig.  4c). We found severe interstitial 
fibrosis of diabetic myocardium indicated by increased 
MT staining (Fig.  4c). Additionally, elevated immuno-
reactivity was observed against the profibrotic mediator 
TGF-β1 and fibrosis marker fibronectin in the diabetic 
heart (Fig.  4c). Application of cinaciguat reduced MT 
staining intensity of diabetic myocardium (Fig. 4c) while 
TGF-β1 immunoreactivity strongly tended to decrease 
(P = 0.051) (Fig. 4c).
DM related myocardium hypertrophy and apoptosis is 
alleviated by cinaciguat
Myocardial mRNA expression data from LV myocar-
dium of diabetic rats showed a marked increase of ANF 
and the β-MHC/α-MHC ratio (Fig. 5a). Treatment with 
cinaciguat caused a significant decrease of ANF expres-
sion in DM (Fig. 5a) while β-MHC/α-MHC ratio showed 
slight decrease (Fig. 5a). When compared with controls, 
increased cardiomyocyte width was observed in the 
DiabCo group indicative of cardiomyocyte hypertrophy. 
This increase was completely prevented by cinaciguat 
(Fig.  5b, c). The mRNA expression levels of proapop-
totic BAX and antiapoptotic Bcl-2 did not differ among 
the study groups resulting in unchanged BAX/Bcl-2 ratio 
(Fig. 5a). DM was associated with increased TUNEL pos-
itivity in LV myocardium referring to pronounced DNA 
fragmentation (Fig.  5b, c). TUNEL positivity was effec-
tively reduced in the DiabCin group (Fig. 5b, c).
In vivo cardiac function is improved by cinaciguat in DM
In comparison with non-diabetic controls DiabCo group 
showed remarkably reduced MAP, LVSP, EF, SW, dP/
dtmax and impaired dP/dtmin values, while LVEDP and 
Tau increased, indicating LV systolic and diastolic dys-
function (Table  2). HR significantly decreased in the 
diabetic groups while CO was not significantly different 
among the study groups (Table 2). MAP, LVSP, SW, dP/
dtmax and dP/dtmin remained unchanged in the DiabCin 
group, however drug treatment markedly improved 
LVEDP and Tau in DM (Table 2). As a result of cinaciguat 
treatment EF tended towards improvement (P =  0.054) 
in DM (Table 2).
The values of load-independent, P–V-loop derived 
contractility indexes (Ees, PRSW) were significantly 
reduced in diabetic animals indicating severe contrac-
tile dysfunction (Fig.  6a, b) Treatment with cinaciguat 
led to a significant increase in PRSW (Fig. 6b) while Ees 
showed a strong tendency towards improvement in DM 
(P = 0.092) (Fig. 6b).
In comparison with Co group the slope of EDPVR 
tended to increase (P  =  0.063) in diabetic animals, 
which was significantly reduced by cinaciguat (Fig.  6b). 
Cinaciguat had no hemodynamic effects in non-diabetic 
rats.
Discussion
In the current study we investigated the effects of the 
sGC activator cinaciguat on DM related cardiac altera-
tions in an experimental type-1 diabetic animal model. 
We found that chronic application of cinaciguat did not 
affect blood glucose levels, however it effectively raised 
cGMP levels and restored cGMP-PKG signalling in the 
myocardium. These molecular changes were associated 
with attenuated cardiomyocyte hypertrophy, less severe 
fibrotic remodelling and markedly improved systolic and 
diastolic cardiac performance.
Rat model of STZ induced type-1 DM is widely used 
in research studies aiming at the characterisation of dia-
betic cardiomyopathy and its possible new therapeutic 
approaches. STZ is taken up via glucose transporter 2 to 
the pancreatic beta cells which ensures its selective toxic-
ity for beta cells and the ability to induce insulin-depend-
ent DM. In the present study increased blood glucose 
and daily water intake levels indicated obvious evidence 
of pronounced DM in STZ-treated rats which was con-
cordant with earlier data [31].
The most important cause in DM that presumably 
leads to severe complications, including diabetic cardio-
myopathy, is hyperglycemia. The imbalance in glucose 
homeostasis triggers numerous mechanisms and signal-
ling pathways which result in cardiovascular dysfunction. 
Despite the fact, that many studies investigated its patho-
logical background so far, the exact pathomechanisms of 
diabetic cardiomyopathy are still poorly understood. It is 
known that hyperglycemia increases production of ROS 
and RNS and subsequent upregulation of endogenous 
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antioxidant systems and overexpression of heat shock 
proteins [32] through several mechanisms [1]. As a 
marker of excessive nitro-oxidative stress [33] a sig-
nificantly higher NT positivity was shown in the dia-
betic myocardium which might have contributed to the 
observed induction of endogenous antioxidant systems 
(see thiorexodin-1, catalase or gluthatione-reductase 
gene expression levels) and to a remarkable heat shock 
response (increased HSP70a1 level). Pronounced nitro-
oxidative stress can lead to the oxidation of the sGC 
enzyme which causes the loss of its heme prosthetic 
group and results in a NO-insensitive (inactive) form of 
sGC. Additionally, an imbalance of the different types 
of phosphodiesterases was presented in the failing heart 
which might have contributed to the rapid degrada-
tion of intracellular cGMP [34]. Decreased cGMP lev-
els and subsequent impairment of NO-cGMP-PKG 
signalling is a well-known feature occuring in the diabetic 
myocardium. This observation was confirmed by our 
results showing reduced myocardial cGMP content in 
diabetic rats while sGC β1 and eNOS protein expression 
remained unchanged. Moreover, NO-cGMP-PKG signal-
ling showed a severe deterioration in the diabetic group 
indicated by a reduced gene expression level of eNOS, 
increased PDE-5 protein levels (in accordance with pre-
vious data [35]) and significantly reduced phosphoryla-
tion of the PKG target VASP (lower p-VASP/VASP ratio, 
an index of PKG activity [23]). However, elevated PKG 
protein expression was observed which might reflect an 
ineffective compensatory mechanism in the LV. The pre-
sumable loss of the widely described cGMP related cyto-
protection was associated with a four times higher extent 
of DNA damage in DM compared with controls (indi-
cated by the TUNEL reaction). The observed discrepancy 
between impairment of myocardial cGMP-signalling and 
unchanged plasma cGMP levels in DiabCo vs. Co ani-
mals might be the consequence of diabetes-associated 
increase in ANF levels and the subsequent activation of 
natriuretic peptide receptors and particulate guanylate 
cyclase (pGC) in organs other than the heart, as plasma 
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Fig. 3 The effect of diabetes mellitus and cinaciguat on myocardial NO‑sGC‑cGMP‑PKG signalling. a Relative protein expression and representative 
immunoblot bands of endothelial nitric oxide synthase (eNOS), soluble guanylate cyclase β1 (sGC β1), phosphodiesterase 5A (PDE‑5) (P value of dia‑
betes × treatment interaction in the two‑factorial ANOVA, Pinteraction = 0.024), protein kinase G (PKG), vasodilator‑stimulated phosphoprotein (VASP) 
to phospho‑VASP (p‑VASP) ratio (Pinteraction = 0.003). b Relative gene expression of eNOS (Pinteraction = 0.039). Groups: vehicle‑treated control (Co), 
cinaciguat‑treated control (CoCin), vehicle‑treated diabetic (DiabCo) and cinaciguat‑treated diabetic (DiabCin). Bar graphs represent mean ± SEM of 
5–6 experiments per group.*P < 0.05 vs. Co, †P < 0.05 vs. DiabCo (Tukey HSD test)
Page 8 of 13Mátyás et al. Cardiovasc Diabetol  (2015) 14:145 
cGMP is seen as an overspill of intracellular cGMP from 
various tissues [36].
The sGC activator cinaciguat has been described to 
exert disease specific effects since it preferentially acti-
vates the oxidised, inactive form of the enzyme (that 
is present mainly in diseased conditions) thus restores 
its cGMP producing ability [17] in various pathologi-
cal conditions associated with excessive nitro-oxidative 
stress [19, 21]. With the application of cinaciguat we 
achieved massive cytoprotective effects in DM, that 
was confirmed by lower NT staining (indicative of 
attenuated nitro-oxidative stress), normalised expres-
sion of endogenous antioxidant and heat shock protein 
systems as well as lower extent of DNA breaks (less 
severe TUNEL positivity). The mechanism by which 
cinaciguat decreased nitro-oxidative stress remains 
unclear and needs further investigations. A possible 
explanation might be the cGMP-induced down-reg-
ulation of NADPH-oxidases, as proposed by a recent 
experimental work [37]. By reducing oxidative damage 
to the myocardium with cinaciguat, pathologically high 
levels of PDE-5 enzyme reversed to the level of control 
animals, which might have contributed to the accumu-
lation of cGMP in the diabetic heart and plasma, too. 
The augmented cGMP production consequently rein-
forced the impaired PKG activity (proven by markedly 
increased myocardial p-VASP/VASP ratio) that further 
contributed to the cardioprotective effects of cinaciguat 
in DM.
Pathological remodelling is a well-known phenom-
enon in the diabetic myocardium, however there are 
several remaining questions regarding the underlying 
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nohistochemistry. Magnification: ×400, Scale bar 40 µm. (n = 9–11/group) c Relative protein expression and representative immunoblot bands of 
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Table 2 Basic hemodynamic data of the study groups
Heart rate (HR), mean arterial pressure (MAP), maximal left ventricular (LV) systolic pressure (LVSP), stroke work (SW), cardiac output (CO), ejection fraction (EF), 
maximal slope of systolic pressure increment (dP/dtmax) and diastolic pressure decrement (dP/dtmin), LV end-diastolic pressure (LVEDP) and time constant of LV 
pressure decay (Tau) are shown. Groups: vehicle-treated controls (Co), cinaciguat-treated controls (CoCin), vehicle-treated diabetic (DiabCo) and cinaciguat-treated 
diabetic (DiabCin) animals. Values are mean ± SEM of 9–11 experiments per group
* P < 0.05 vs. Co
† P < 0.05 vs. DiabCo (Tukey HSD test)
Variable Co CoCin DiabCo DiabCin Pdiabetes Ptreatment Pinteraction
HR (beats/min) 231 ± 11 246 ± 12 208 ± 8* 204 ± 10* 0.003 0.608 0.351
MAP (mmHg) 80.0 ± 2.0 81.0 ± 3.5 63.7 ± 2.5* 64.4 ± 3.1* <0.001 0.845 0.969
LVSP (mmHg) 99.5 ± 2.6 103.5 ± 2.1 85.5 ± 1.3* 82.3 ± 2.3* <0.001 0.858 0.102
SW (mmHg µl) 14,561 ± 1060 13,293 ± 948 9789 ± 592* 12,032 ± 1067 0.003 0.611 0.072
CO (µl/min) 42,347 ± 2472 41,306 ± 2804 33,360 ± 2162 38,605 ± 4288 0.057 0.484 0.297
EF (%) 70.42 ± 2.50 68.17 ± 2.70 58.09 ± 2.54* 68.02 ± 2.56 0.021 0.146 0.024
dP/dtmax (mmHg/s) 6539 ± 240 6804 ± 188 4933 ± 207* 4785 ± 230* <0.001 0.791 0.350
dP/dtmin (mmHg/s) −6135 ± 362 −6570 ± 446 −3883 ± 133* −3723 ± 248* <0.001 0.679 0.374
LVEDP (mmHg) 7.0 ± 0.6 7.2 ± 0.4 9.7 ± 0.7* 6.8 ± 0.3† 0.026 0.082 0.034
Tau (Weiss; ms) 10.3 ± 0.3 10.1 ± 0.3 17.3 ± 0.8* 14.9 ± 0.6*† <0.001 0.016 0.054
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mechanisms to be clarified. A number of key patho-
physiological features such as cardiac hypertrophy, 
fibrotic remodelling, myocardial tissue injury with 
DNA fragmentation are lying in the background of 
diabetic cardiomyopathy [1]. In our diabetic rat model 
pathological cardiomyocyte hypertrophy was devel-
oped demonstrated by increased cardiomyocyte diam-
eter, increased ANF gene expression values and a shift 
in the β/α-MHC expression ratio. Chronic pharma-
cological activation of sGC showed antihypertrophic 
effects not only on the histological level (decreased 
cardiomyocyte diameter) but also in the molecular 
environment (significantly reduced ANF gene expres-
sion, strong tendency towards reversed shift in β/α-
MHC ratio). Our results are concordant with data 
from a recent publication [23] demonstrating anti-
hypertrophic and antifibrotic effects of cinaciguat 
in cultured cells. Fibrotic remodelling of the diabetic 
myocardium is strongly associated with dysregula-
tion of MMPs [1], increased fibroblast proliferation 
[38], decreased Col1 and Col3 mRNA expression [39] 
and TGF-β1 signalling [40]. In accordance with pre-
vious literature data we found an upregulation of the 
profibrotic mediator TGF-β1, downregulation of Col1 
and Col3 mRNA levels, intense MT and fibronec-
tin staining (as fibrosis markers) and increased DNA 
fragmentation in diabetic cardiomyopathy. Data from 
our experiments revealed that treatment with the sGC 
activator cinaciguat effectively prevented pathologi-
cal changes in the myocardium by improving MMP 
dysregulation (reverting altered MMP-9/TIMP-1 
and MMP-2/TIMP-2 ratios), by decreasing myocar-
dial level of TGF-β1 and preventing fibrotic changes, 
as well as repressing myocardial TUNEL positivity. 
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Interestingly, we did not find any differences in BAX/
Bcl-2 ratio among the study groups which suggest that 
classical apoptotic pathways are not involved in the 
observed beneficial effects. A possible explanation 
might be a cross-talk between sGC-cGMP axis and 
TGF-β-dependent extracellular signal-regulated kinase 
signalling (as reported by Beyer et  al. [41]), however 
this hypothesis requires further investigations.
Several clinical and experimental studies have 
focused on the investigation of cardiac function in 
DM. Both systolic and diastolic dysfunctions have 
been described in type-1 diabetes in the literature 
using different non-invasive and invasive methods 
[2, 31]. We found similar alterations in our current 
study regarding DM related cardiac dysfunction. We 
observed a significant reduction of MAP (probably as 
a consequence of diabetic polyuria [42]) in DM com-
pared with controls that was not affected by chronic 
cinaciguat treatment. Whether cinaciguat adminis-
tration acutely affects MAP in diabetic rats, needs 
further non-invasive investigations. DiabCo group 
showed significantly deteriorated systolic function (as 
reflected by decreased LVSP, SW, EF and dP/dtmax). 
EF and dP/dtmax are widely used to assess contractile 
function, however they are known to be affected by 
pre- and afterload [29]. Therefore, in the present study 
we determined P–V-loop derived, pre- and afterload 
independent contractility parameters (Ees, PRSW) that 
are more informative on intrinsic myocardial contrac-
tile function [29]. The specific indexes of LV contrac-
tility showed severe systolic dysfunction in the DiabCo 
group. As a result of sGC activation a remarkable 
improvement of systolic function has been achieved 
in diabetic animals: a significant increase of PRSW 
clearly reflects improved LV contractility, whereas EF 
and SW were restored to the levels of healthy con-
trols. When investigating diastolic function we found 
significantly deteriorated LV active relaxation (as 
shown by impaired dP/dtmin and prolonged Tau) and 
markedly elevated LV diastolic stiffness (indicated by 
higher LVEDP and strong tendency towards increased 
EDPVR) in DM compared with controls. Cinaciguat 
effectively improved not only active relaxation (by 
remarkably shortening Tau) but also diastolic stiffness 
(by reverting LVEDP and EDPVR values).
Study limitations: Results in the current study are 
limited to young, male, type-1 diabetic rats. Rats did 
not receive any glucose-lowering medication. Acute 
effects of pharmacological activation of sGC on hemo-
dynamics were not investigated. A possible explana-
tion of cinaciguat’s beneficial effects in DM could be the 
improvement of cardiac microvascular perfusion, how-
ever that needs further investigations.
Conclusions
To our knowledge, this is the first study reporting the 
effects of pharmacological sGC activation on diabetic 
cardiomyopathy and DM related myocardial dysfunction. 
We confirmed that the sGC activator cinaciguat improves 
pathological features of diabetic cardiomyopathy without 
affecting blood glucose levels. Molecular mechanisms 
underlying the advantagous effects of sGC activation 
include the upregulation of NO-sGC-cGMP-PKG axis 
which might crosstalk with antioxidant, antihypertrophic 
and antifibrotic cascades hence preventing cardiac com-
plications of diabetic metabolism and improving DM 
related cardiac dysfunction. Based on the data presented 
here pharmacological sGC activation might be a poten-
tial therapeutic approach to improve cardiovascular dys-
function in DM.
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